COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial (QUASAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02446795
Recruitment Status : Unknown
Verified January 2017 by Consorzio Oncotech.
Recruitment status was:  Recruiting
First Posted : May 18, 2015
Last Update Posted : January 18, 2017
Clinical Research Technology S.r.l.
Quercegen Pharmaceuticals
Information provided by (Responsible Party):
Consorzio Oncotech